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Abstract: The last two to three decades have seen an explosive growth in interest and 
information regarding cardiovascular disease (CVD) risk assessment and treatment. Evidence 
for the role of low-density lipoprotein (LDL) in risk has led to a series of clinical guidelines/
recommendations on the importance of LDL lowering with statin treatment. There is also 
substantial evidence on a number of lipoproteins in the initiation and progression of athero-
sclerosis and CV events. Health care professionals have not embraced easily novel approaches 
to identifying those at increased risk and more aggressive treatment. This is especially true 
for non-LDL factors. The use of non-statin drugs such as fibrates has been modest and many 
health care professionals avoid consideration of combination therapy due to an inordinate fear 
of toxicity. This review will attempt to provide appropriate background information on lipids/
lipoproteins, including non-high density lipoprotein and risk, as well as data available on fibrates 
and combination pharmacologic therapy. We will review a new agent, TriLipix® (fenofibric 
acid), and its potential role in treatment.
Keywords: dyslipidemia, peroxisome proliferated activated receptors, fibrate, fenofibric acid, 
TriLipix, very-low-density lipoprotein, triglycerides, non-high density lipoprotein
Introduction
Traditional laboratory evaluation used in clinical medicine includes measurement 
of total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL) and 
high-density lipoprotein (HDL). Cholesterol is the most abundant steroid in animal 
tissue. The other major neutral lipid is formed by combining a three carbon glycerol 
(an alcohol) with three fatty acids (acyl groups) to form triacylglycerol, also known as 
TG. TG are the major form of circulating fat and are used as a prime source of energy. 
These hydrophobic lipids (Figure 1) are poorly soluble and have to be transported 
in the aqueous plasma by a variety of lipoproteins. The core of plasma lipoproteins 
contain cholesterol ester (CE) and TG surrounded by phospholipids with their more 
soluble polar phosphate groups pointing out to the surface of the particle. Lipoproteins 
also contain one or more apoproteins on their surface which are major determinates of 
the biochemical and metabolic activities of these particles (Figure 2). Dietary TG are 
absorbed via the intestine and transported in chylomicrons. Endogenous production 
also occurs in the liver. TG enter the circulation from the liver mainly in the core of 
very-low-density lipoprotein (VLDL).
Laboratory assessment and subsequent clinical use of plasma lipid measurements 
have provided an important means for CVD risk assessment and a guide to treatment. 
Standard laboratory tests measure neutral lipids; however, CE and TG, contained Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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within various circulating lipoproteins, do not provide 
information on the number, biochemical or metabolic 
characteristics of specific particles. We have been trained to 
relate CVD risk to TC and LDL; however the Framingham 
study revealed the mean LDL of subjects who developed CV 
events versus those who did not during long term follow-up 
was not significantly different.1 The National Cholesterol 
Education Program (NCEP) Adult Treatment Panel (ATP) 
has made three major consensus statements which include 
recommendations for lipid goals in patients at risk2 (Table 1). 
However we do not define what constitutes a “normal” 
LDL in specific individuals. Definition of “elevated” LDL 
and determination to treat with LDL-lowering strategies 
are based on risk stratification using the presence of other 
concomitant traditional risk factors. We do not recommend 
LDL lowering in adults without grossly elevated LDL unless 
they also have other risk factors present.3 The Framingham 
Risk Score assigns points for sex, age, cigarette smoking, 
systolic blood pressure, TC, and HDL. The total number of 
points for any individual is used to estimate their “absolute 
risk” of developing a CV event over the ensuing 10 years. 
High risk is defined as .20%, intermediate 10% to 20% 
and low risk ,10%. The NCEP ATP modified and simpli-
fied the Framingham approach but again based treatment 
recommendations on the number of risk factors present. The 
initial NCEP ATP III recommendations included an LDL 
goal of ,100 mg/dL in those with prior CV events. However 
based on the results of aggressive LDL-lowering trials 
utilizing higher doses and more potent statins providing fur-
ther RRR4–6 the ATP III panel in 2002 produced a “footnote” 
with the statement that in the “highest risk group of patients 
an LDL goal of #70 mg/dL is optional”.7 However the 
same primary author had earlier raised concern over what 
appeared to be attenuation of more aggressive LDL lowering 
with statins on relative risk reduction (RRR) when previous 
recommended LDL goals had already been attained.8 The 
continued occurrence of the majority of predicted CV events, 
even in those aggressively treated and attaining LDL goals, 
is now termed residual risk. This issue was again raised in 
a controversial analysis by Hayward et al published in 2006 
raising a question of whether more aggressive LDL lowering 
with higher dosage and more potent statin treatment was 
supported by the data. The authors evaluated published statin 
trial data and calculated the number-needed-to-treat (NNT) 
to prevent a CV event in the secondary risk population when 
reducing LDL from .200 mg/dL to 100 mg/dL to be 1:20. 
However, the NNT obtained by further reducing LDL from 
100 mg/dL to 70 mg/dL or less was 1:67, comparable to the 
RRR noted in primary prevention trials using statins.9,10 Their 
conclusion was that the data was not robust enough to warrant 
the more aggressive optional treatment recommendation of 
LDL #70 mg/dL due to potential for increased side effects, 
toxicity and cost.11
Multiple lipoproteins, all of which transport CE and 
TG, depending on their surface apoproteins, may have 
variable atherogenic, protective, or both, potentials. 
Penetration and retention of apoB particles, including LDL, 
in the subendothelial space appear to initiate a process 
leading to inflammation, plaque formation and eventually 
atherothrombotic events.12 However, other lipoproteins and 
inflammatory factors obviously contribute to the process 
and more information regarding specific lipoproteins and 
their behavior may further improve risk stratification and 
treatment. The atherogenic dyslipidemia characterized by 
increased TG and decreased HDL is now commonly associ-
ated with increased waist circumference, metabolic syndrome 
(MS) and type II diabetes.13 CV events and mortality are 
increased in these dysmetabolic states and may be related 
to non-LDL factors.
Triglycerides
A number of hereditary/familial disorders featuring or 
including increased TG play a role in CVD risk. Familial 
hypertriglyceridemia (FHTG) is a fairly common inher-
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ited disorder of uncertain origin. TG are commonly 200 to 
1000 mg/dL with normal or mildLy elevated cholesterol 
(.240 mg/dL). LDL is not usually increased. It appears to 
be inherited as an autosomal dominant trait but is not usually 
expressed until adulthood. It occurs in 1/500 people. Familial 
dysbetalipoproteinemia or type III hyperlipoproteinemia 
creates a defect in apoE leading to accumulation of abnormal 
elevated chylomicrons and VLDL in the plasma. Patients 
have both increased TG and TC, usually to a similar degree. 
HDL is usually within normal limits. These patients can have 
tuboeroeruptive xanthomas (elbows, knees or buttocks) and 
palmar xanthomas. Premature coronary artery disease (CAD) 
is common and aggressive evaluation and treatment, includ-
ing combination therapy, is often needed. Familial combined 
hyperlipidemia (FCHL) is a mixed dyslipidemia with mod-
erately elevated fasting TG, TC and decreased HDL. Hepatic 
overproduction of VLDL is the common basis of this familial 
defect which may occur in 1/200 persons, commonly in those 
with premature CAD. Fasting TG in the range of 200 to 
800 mg/dL and TC 200 to 400 mg/dL are common. Prominent 
family history supports the diagnosis. Significantly elevated 
apoB levels, disproportionate to LDL, is often noted. Patients 
with FCHL require aggressive treatment and follow-up due 
to significant CVD and event risk.
Increased fatty acid levels occur with increased waist 
circumference, obesity, MS, diabetes and post-prandial 
lipemia which stimulate hepatic production and secretion 
of VLDL resulting in increased serum TG. This in turn has 
a significant effect on the number, size, composition and 
density of almost all lipoproteins with increased number 
of VLDL remnant particles, including intermediate density 
lipoprotein (IDL) and small dense LDL particles. This 
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Figure 2 Apo B lipoprotein with neutral lipids contained in the core.
Reproduced with permission from Koschinsky ML, Marcovina SM. In: Ballantyne, CM, editor. Clinical Lipidology: A Companion to Braunwald’s Heart Disease. Philadelphia: Saunders 
elsevier; 2009:130–143.13 Copyright © 2009 elsevier.
Table 1 Optimal lipid goals in high risk patients.
Male Female
LDL ,100 mg/dL ,100 mg/dL
HDL .40 .50
TG ,150 ,150
Non-HDL ,130 ,130
Notes:  Consistent  with  published  recommendations  from  the  NCEP  ATPIII, 
American Heart Association and American Diabetes Association.
Abbreviations:  HDL,  high-density  lipoprotein;  LDL,  low-density  lipoprotein; 
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results from the inability of lipoprotein lipase to adequately 
delipidate (exchange and remove CE and TG from the core of 
lipoproteins) VLDL and properly clear the remnant particles 
from the circulation. HDL is similarly affected with the 
production of increased small, denser particles with less Apo 
A-I, increased catabolic rates and therefore reduced HDL. 
This process may also lead to increased numbers of, with 
a variety of isoform heterogeneity, lipoprotein(a) [Lp(a)] 
particles. Lp(a) has a complex structure consisting of an LDL 
particle covalently bound to a glycoprotein, apolipoprotein(a) 
[apo(a)]. The apo(a) contains multiple repeated kringle 
sequences similar to the sequence found in the fibrinolytic 
proenzyme plasminogen. This similarity of the LDL-Apo(a) 
or Lp(a) to plasminogen might provide a link between the 
processes of atherosclerosis (LDL) and thrombosis. The plas-
minogen-like apo(a) competes with plasminogen and inhibits 
it’s fibrinolytic activity. However the varying Lp(a) isoforms, 
difficulty with accurate and reproducible laboratory mea-
surement, resistance of Lp(a) lowering with pharmacologic 
treatment and the lack of outcome data continue to make 
approaches to Lp(a) speculative at best.13 Even excluding the 
possible role of Lp(a), from the clinical standpoint the overall 
result of this dyslipidemia is enhancement of the atherogenic 
potential of the circulation.14
Although TG appear to play a role in CV events, severely 
elevated TG (.500 mg/dL) are associated with increased risk 
of acute pancreatitis and at very high levels may increase 
risk of in situ thrombosis.
Although beyond the scope of this review, lifestyle 
modification to address a variety of dysmetabolic states, 
including certain dyslipidemias and risk, associated with 
elevated TG is always part of the therapeutic strategy. Diet, 
exercise and decreased alcohol intake when necessary can 
quickly and dramatically lower free fatty acids and TG, 
resulting in decreased non-HDL and VLDL.
Non-LDL risk
The Framingham Heart Study has provided cogent data 
consistent with the important role of HDL in CVD risk. A 1 mg/
dL difference in HDL level is inversely associated with a 1% to 
2% difference in CV risk.15–17 The important role of elevated TG 
in CVD risk is supported by the often quoted large meta-analysis 
by Hokanson and Austin18 (Figure 3) in addition to data from the 
10-year study of the Caerphilly and Speedwell Cohorts.19 The 
Copenhagen Male Study20 followed 2906 men without known 
CVD for 8 years and The Prospective Cardiovascular Munster 
Study (PROCAM) Study21 4849 men for up to 8 years, all with-
out known CVD. These studies consistently reveal the relation-
ship between TG and CV events independent of other known 
major risk factors as well as HDL. These data, however, are 
just as consistently questioned because the tightest relationship 
occurs when also associated with either elevated LDL or 
decreased HDL. Genest described the prevalence of a variety 
of lipoprotein disorders in 102 kindreds (n = 603) with prema-
ture coronary artery disease (CAD) documented by coronary 
arteriography.22 More than half of the patients had a familial 
lipoprotein disorder with the most common being hypertrig-
lyceridemia with hypoalphalipoproteinemia (decreased apo 
A-1), excess Lp(a) and combined hyperlipidemia (Figure 4). 
Genest et al also reviewed the role of LDL, HDL and TG in men 
with premature CAD and found that both initial TG and HDL 
levels, but not LDL correlated with significant angiographic 
disease23 and followed this with further investigation indicating 
the need for more aggressive evaluation of lipoprotein status 
in these patients. An appropriate and logical conclusion is that 
no single lipoprotein parameter will identify the majority of 
patients at risk and with significantly increased LDL, although 
a strong association with the development of CAD is actually 
an infrequent finding in patients with premature CAD.
Increased TG-rich lipoproteins have significant adverse 
effects on HDL composition, number, size, density, apoA-1 
content and function. Recent reanalysis of CARE and 
PROVE-IT24 reveal that recurrent clinical events even after 
aggressive LDL lowering are directly related to HDL and TG 
levels, respectively. Non-HDL (TC-HDL) now appears to be 
a more powerful CVD risk predictor than LDL25 treatment 
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Figure 3 increases in triglycerides associated with increases in CHD risk: a meta-
analysis of 17 prospective studies.
Notes: For every increase in serum TG level of 89 mg/dL, the risk of CHD increases 
32% in men and 76% in women. The 17 prospective studies reporting association 
between elevated TG and CV endpoints included 46,413 men with 2445 events 
(average follow-up 8.4 years) and 10,864 women with 439 CV events (average 
follow-up 11.4 years).
Abbreviations:  CHD,  coronary  heart  disease;  CV,  cardiovascular;  TG, 
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recommendations for non-HDL lowering have been developed 
and included in the ATP III recommendations. Non-HDL is 
directly related to serum TG levels and is an indicator of the 
number of apoB atherogenic particles including VLDL and its 
remnant particles LDL, IDL, and Lp(a). It is not uncommon 
to have patients with LDL that does not appear significantly 
elevated or is at the NCEP ATPIII recommended goal but 
continue to have an elevated non-HDL (30 mg/dL greater than 
LDL). This population requires more aggressive treatment 
aimed at further decreasing the number of apoB particles, 
which can be addressed in a number of ways.
Combination pharmacologic treatment
Clinical trials utilizing non-statin or combination therapy 
(statin + fibrate), especially in specific populations (MS, 
diabetes, elevated TG and non-HDL, decreased HDL), have 
revealed significant CV event reductions in both the primary 
and secondary risk groups. The Helsinki Heart Study, a 
primary prevention trial in hypercholesterolemic subjects, 
included more then 4000 men without known CVD. Over 
a 4-year follow-up those treated with gemfibrozil exhib-
ited increased HDL with reductions in TG, non-HDL, and 
LDL. There was a 35% decrease in CV events in the treated 
group. Those with high LDL:HDL ratios (.5) and elevated 
TG (.200 mg/dL) had the highest event rates and greatest 
benefit from treatment.26 The Bezafibrate Post-Infarction 
Study evaluated subjects in this highest risk group for recur-
rent events. In those with elevated TG and fitting criteria for 
MS, bezafibrate significantly reduced recurrent CV events 
versus placebo.27 The Stockholm Ischaemic Heart Disaese 
Study treated subjects post-mycardial infarction (MI) with 
clofibrate plus niacin versus placebo. Coronary heart disease 
death was reduced by 36% and total mortality by 26% over 
5 years28 without evidence of increased muscle or hepatic 
toxicity. The VA-HIT Study randomized more than 2200 
post-MI subjects with baseline mean LDL 111 mg/dL and 
HDL 32 mg/dL. The treatment group received 1200 mg/day 
of a long-acting gemfibrozil daily without concomitant statin. 
Mean TG decreased by 30% and HDL increased by 6%. The 
treatment group had a reduction in the primary end-point, 
mortality and non-fatal MI by 24%.29 Patients with diabetes 
exhibited the greatest reduction. The controversial FIELD 
Trial used fenofibrate in patients with diabetes but without 
known CAD or typical diabetic dyslipidemia (elevated TG, 
decreased HDL). Fenofibrate did not significantly reduce the 
risk of the primary outcome of coronary events. It did reduce 
total CV events (13.9% to 12.5%; P = 0.035) due to fewer 
non-fatal MI and revascularization. Major reductions in laser 
treatment for retinopathy, occurrence of albuminuria, and 
amputations were documented.30 In March 2010 the Effects 
of Combination Lipid Therapy in Type 2 Diabetes Mellitus, 
an NIH study with support from multiple industry partners, 
was published.31 5518 patients with diabetes who were being 
treated with open label simvastatin were randomized to either 
simvastatin/fenofibrate or simvastatin/placebo. Subjects had 
known clinical CVD or diabetes plus 2 or more risk factors. 
After a mean follow-up of 4.7 years there was no difference 
in the primary end-point of non-fatal MI, non-fatal stroke 
or CV death between the groups. The combination of statin/
fenofibrate did not increase RRR for events. These studies 
do not support the routine use of combination treatment in 
patients with diabetes; however, the concern about both the 
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Figure 4 Prevalence of dyslipidemias in men ,60 years with angiographic evidence of coronary atherosclerosis. Drawn from data of Genest et al.23
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FIELD and the ACCORD lipid studies is that neither evalu-
ated patients with significant diabetic/atherogenic dyslipi-
demia, especially considering background prior treatment 
with statin. Superko and King compared several clinical 
end-point and angiographic regression studies for efficacy 
in reducing CV events (Figure 5). Across a variety of tri-
als using combination lipid-modifying therapy produced 
an average RRR of 71.6% and a NNT of 9.6. Analysis of 
these data reveal significantly enhanced efficacy for event 
reduction with combination LDL and non-HDL lowering 
(decreased TG and increased HDL) compared with LDL 
lowering with statins alone.32 Confronted with the limited 
current maximized RRR of statin monotherapy for LDL 
lowering (Figure 6), it is time to recognize the potential of 
a more comprehensive and aggressive approach to global 
lipid/lipoprotein modification with combination therapy for 
CVD prevention.
Fibrate therapy
Fibrates have been used clinically since the late 1960s. This 
drug group includes clofibrate, bezafibrate, gemfibrozil, 
ciprofibrate and most recently fenofibrate. The fibrates 
are synthetic ligands that bind to nuclear peroxisome 
proliferator-activated receptors (PPAR). The PPARs are 
nuclear transcription factors that potentially play a role in 
the regulation of hundreds of genes. There are three receptor 
isoforms including PPAR-alpha (α), PPAR-gamma (γ) 
and PPAR-delta (δ) encoded by different genes. They are 
ligand-regulated nuclear hormone receptors and when 
activated by an agonist result in increased gene transcription, 
messenger RNA production and protein synthesis. The PPARs 
appear to play a significant role as sensors and regulators of 
lipid metabolism.33 Fatty acids and eicosanoids are natural 
PPAR ligands. Fibrates and thiazolidinediones (TZD) are 
potent PPAR ligands and have well documented effects on 
lipid and glucose metabolism in addition to atherosclerosis 
and vascular inflammation. PPAR(α) appears to play an 
important role in fatty acid metabolism. Mechanisms 
that lead to TG lowering include suppression of hepatic 
apo-CIII gene expression and stimulation of lipoprotein 
lipase (LPL) transcription,34 which promote increased cellular 
fatty acid uptake, oxidation and decreased production. 
Subsequently increased catabolism of TG-rich lipoproteins 
including VLDL and its remnant particles occurs, leading 
to decreased TG and non-HDL levels. Upregulation of apo 
A-I and A-II increase plasma HDL.35 PPAR(α) activation 
may improve HDL function, including reverse cholesterol 
transport and anti-inflammatory activity.36 Fibrates also 
reduce the magnitude and duration of post-prandial lipemia 
in those with hypertrycleridemia. Additional effects include 
anti-inflammatory actions with decreased in vitro expression 
of vascular adhesion molecule-1, and suppression of 
monocyte-macrophage migration37,38 and chemoattractant 
protein-1 (MCP-1), and are associated with reduced inflam-
matory markers including hsCRP, lipoprotein-associated 
phospholipase A2 (Lp-LPA2), interleukin-6, fibrinogen and 
tumor necrosis factor-alpha.39,40 Fenofibrate increased adi-
ponectin levels, improved insulin sensitivity and significantly 
improved flow-mediated dilator response to hyperemia, a 
measure of endothelial function, in hypertriglyceridemic 
and MS patients.41,42 Whether all of these metabolic effects 
play a role in reducing atherosclerosis and CV risk remains 
in question.
Concern over potential toxicity of combination 
lipid-modifying therapy along with limited outcome data 
available has discouraged use by health care professionals 
even in those in the highest-risk group for recurrent CV events. 
Combination lipid treatment does not have documented 
significant increased side effects or toxicity especially in 
comparison to combination treatment for other CV conditions. 
Currently 30% of Americans with hypertension meet blood 
pressure goals (,140/90) and the average number of drugs 
required in uncomplicated cases is 2.4. This number increases 
to 3.4 in those with diabetes or renal dysfunction. Current 
guidelines recommend 3 drugs in those with systolic heart 
failure and diabetes patients often require multiple agents for 
acceptable glucose and hemoglobin A1c control. These drug 
classes and combinations have been associated with frequent 
side effects and occasional toxicity. There are few data, and 
in fact no powerful retrospective or prospective studies or 
randomized trials that reveal significant increased risk for 
hepatic, renal or muscle toxicity with any lipid-modifying 
combination therapy. There is a small increase in muscle 
toxicity when using statin/gemfibrozil combination. This risk 
has not been documented with statins and other fibrates.43–45 
There is little published information on safety and toxicity 
of nicotinic acid or high dose omega-3 use with fibrates. 
However, clinical experience and reports in small patient 
groups have not revealed questionable signals or increased 
toxicity. Fenofibrate also appears to be effective and safe 
when used with ezetimibe alone46 or with the combination 
pharmaceutical ezetimibe/simvastatin.47
Mild or modest increases in serum creatinine levels 
have been documented with fenofibrate and ciprofibrate.48,49 
These increases were reversible during the course of 
the trials and the mechanism appears to be increased Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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creatinine production and not a decrease in glomerular fil-
tration rate (GFR).50,51 Subjects with GFR of 30 to 60 mL/
min/1.73 m2 in the Veterans Affairs High-density Lipopro-
tein Intervention Trial (VA-HIT) exhibited no change in 
GFR with gemfibrozil treatment compared to placebo after 
5 years, including those with diabetes or MS. There were 
transient increases in creatinine in 10% of the subjects in 
the treatment group and 4% in the placebo group which 
were not statistically significant.52 Fibrates do not appear to 
increase the risk of acute renal dysfunction and have been 
shown to reduce progression of microalbuminuria in those 
with type II diabetes.49,53 The National Kidney Foundation 
and the National Lipid Association recommend that in stage 
2 or greater chronic kidney disease fibrate monotherapy 
should be used with caution and the dose of fenofibrate 
reduced for those with GFR 30 to 60 mL/min/1.73 m2, 
and avoided in end-stage renal disease. Gemfibrozil may 
have some modest benefit in those with GFR less than 30 
mL/min/1.73 m2; however fenofibrate appears safer when 
used in combination with statins. Davidson et al provide 
a comprehensive evidenced-based presentation of safety 
issues related to fibrate therapy and review and summarize 
all the issues.45
Fenofibric acid is not an inhibitor of the CYP P450 
and has no significant drug-drug interactions in this 
regard. Gemfibrozil and fenofibrate when used with 
coumarin-type anticoagulants may prolong the prothrombin 
time and international normalized ratio (INR). Routine INR 
determinations and follow-up, as always, are recommended 
with dose adjustment as necessary. However, it does not 
appear that fibrates in general represent a unique or significant 
problem for this interaction.
Fibrates most pronounced effects on serum lipids include 
a 30% to 50% reduction in fasting TG as well as reducing 
the duration of post-prandial lipemia by decreasing fatty 
acid synthesis and increasing lipoprotein lipase activity. 
The higher the baseline TG the greater the reductions 
may be.54–56 As a result there is a significant decrease in 
Figure 5 The average RRR for CV events in the secondary population even in the most intensive statin studies is 30%. This leaves significant residual risk for recurrent events. 
Superko and King32 compared a variety of studies utilizing LDL lowering versus LDL lowering and HDL elevation. This latter combined approach resulted in projected RRR 
of 71% to 6% with a NNT of 9.6 overall and 3.4/year.
Abbreviations: CV, cardiovascular; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein a; NNT, number needed to 
treate; RRR, relative risk reduction; TG, triglycerides.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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the production of TG-rich lipoproteins, VLDL and its 
remnant particles57, and commonly an increase in HDL. 
Reducing TG-rich lipoproteins reduces cholesterol ester 
transfer protein-mediated exchange of TG and CE between 
lipoproteins. This reduces TG enrichment of HDL, leading to 
decreased metabolic modification by hepatic lipase, increased 
HDL particle size and decreased catabolism. Fibrates also 
increase hepatic apo-A1 production and HDL precursors. 
These mechanisms increase HDL levels anywhere from 5% 
to 30% and may improve HDL function.
Fibrates have limited TC- and LDL-lowering efficacy. 
They may reduce LDL 10% to 20% in patients with 
hypercholesterolemia and normal baseline TG.54–57 
A corresponding 10% to 20% reduction in apoB levels also 
occurs. When TG levels are elevated fibrate treatment may 
be associated with an increase in LDL cholesterol whether 
calculated by the Friedewald formula or directly measured. 
Although this may raise concern, because of our current 
LDL-centric approach to risk stratification and treatment 
guidelines, it is due to a decrease in TG and an increase in CE 
content in the core of LDL and other apoB particles, result-
ing in larger LDL particle size with a decrease in particle 
number.58,59 This, along with a decrease in VLDL, apoB levels 
and non-HDL, reduce atherogenic risk and CV events.
In recent years a number of studies have been published 
on the safety of the most commonly used lipid-modifying 
treatment, statins, with fenofibrate. Ellen and McPherson 
evaluated 80 patients with combined hyperlipidemia and 
either known CAD or with 3 or more risk factors. They 
received low-dose statin (pravastatin 20 mg or simvastatin 
10 mg) and fenofibrate (300 mg or 200 micronized form) for 
a total of 220.6 patient-years on combination therapy. When 
fenofibrate was used combined with low-dose   statin a marked 
improvement in all lipid measurements was observed. The 
decrease in the TC/HDL ratio, considered a reliable indicator 
of CV event risk, was 24% with fenofibrate alone, 29% with 
statin monotherapy and 40% with the combination therapy. 
In this small group of patients there was no significant 
increase in muscle, liver or renal toxicity or side effects.43 A 
number of other studies using combination treatment with 
statin and fenofibrate also revealed expected results on lipid 
parameters: all exhibited statistically significant decreases 
in TG, LDL, non-HDL, TC/HDL, in addition to hsCRP, and 
increases in HDL, with no increased organ toxicity.30,44,60
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Figure 6 Residual CVD risk in patients treated with intensive statin therapy.
A closer look at 3 trials investigating intensive LDL-C lowering with statin therapy in patients with CHD revealed that residual CVD risk remains in these patients even 
after aggressive LDL cholesterol lowering therapy. All 3 trials compared LDL-C lowering to ~100 mg/dL with more intensive LDL-C lowering to ~70 mg/dL as a means 
of preventing major CVD events in patients with a history of CHD or acute coronary syndromes. In the Pravastatin or Atorvastatin Evaluation and Infection Therapy-
Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) study (N = 4162), pravastatin 40 mg reduced LDL-C to 95 mg/dL and atorvastatin 80 mg reduced LDL-C to 62 
mg/dL in patients who had been hospitalized for an acute coronary syndrome. After 2 years, 22.4% of patients treated with intensive statin therapy (atorvastatin 80 mg/dL) 
suffered a major CVD event.4 In the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) study (N = 8888), simvastatin 20 mg reduced LDL-C 
to 104 mg/dL and atorvastatin 80 mg reduced LDL-C to 81 mg/dL in patients with a history of acute myocardial infarction. After 4.8 years, 12.0% of patients experienced a 
major CVD event even after intensive LDL-C lowering with statin therapy (atorvastatin 80 mg).6 Finally, in the Treating to New Targets (TNT) study (N = 10,001), 10 mg 
atorvastatin reduced LDL-C to 101 mg/dL and 80 mg atorvastatin reduced LDL-C to 77 mg/dL in patients with stable CHD. After 4.9 years, a major CVD event occurred in 
8.7% of patients receiving intensive statin therapy (80 mg atorvastatin).5
These 3 trials reveal that significant residual CVD risk remains in patients even after intensive statin treatment.
Abbreviations: CVD, cardiovascular disease; CHD, coronary heart disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Mixed dyslipidemia and cardiovascular risk
Farnier et al studied the combination of ezitimibe/
statin with fenofibrate in a multi-center double-blinded, 
placebo-controlled trial in a total of 641 subjects with com-
bined dyslipidemia randomized to 4 different treatment arms. 
Combination therapy reduced LDL, TG and non-HDL levels 
by 46%, 50% and 51% in, respectively. ApoB was further 
reduced and HDL and apo A-1 levels increased with com-
bination treatment. There was improvement in LDL pattern 
moving toward less dense larger particles (Pattern B to Pattern 
A). There was no significant increase in side effects or organ 
toxicity.47 A trial with fenofibrate 160 mg/day combined with 
colesevelam 3.75 g/day (a bile acid sequestrant) produced 
greater reductions in LDL and apoB, without significant 
difference in HDL or TG, than fenofibrate alone.61 No sig-
nificant safety issues were noted.
The clinical studies noted are consistent with significant 
CV benefits with fibrate use. However this frequently appears 
confusing to clinicians due to a variety of factors. The playing 
field that fibrates, or any additional lipid-modifying therapy, 
face includes massive, paradigm-changing, randomized trials 
using statin monotherapy commonly in broader and less 
complicated subject populations. Beneficial effects in fibrate 
trials have frequently been noted in subsets of patients, with 
fewer subjects therefore often looked on with unwarranted 
suspicion. Fibrates also have significant multiple lipid/
lipoprotein-modifying effects which may have substantially 
greater impact than realized to date. They have a myriad of 
other metabolic and vascular effects, as noted earlier, perhaps 
helping to regulate hundreds of genes, and probably play 
important roles that are not explained by their lipid-modifying 
effects, including improving insulin sensitivity and reducing 
vascular inflammatory processes.
TriLipix®: a new fibrate
Previously available fenofibrates are pro-drugs which 
require de-esterification in the liver to fenofibric acid, the 
active drug, which is than released into the plasma bound 
to albumin and transported to tissues where PPAR(α) 
is expressed (liver, vascular endothelium, adipocytes, 
muscle cells). The Food and Drug Administration (FDA) 
recently approved TriLipix® (Abbott Laboratories), a 
delayed-release choline salt of fenofibric acid which is not 
a pro-drug (Figure 7). The data presented are taken directly 
or consistent with the FDA-approved package insert.62 
TriLipix requires no hepatic modification in order to acti-
vate PPAR(α). It dissociates in the intestine releasing its 
choline group and active fenofibric acid. The formulation 
comes in 2 strengths, 45 and 135 mg. The capsules contain 
multiple mini-tablets containing hypromellose to extend 
release and are enterically coated to prevent dissociation in 
the acidic environment of the stomach. Fenofibric acid has 
poor solubility at gastric pH but excellent at intestinal pH. 
Absolute bioavailability is in excess of 80%. Peak plasma 
concentration occurs at 4 to 5 hours after oral administra-
tion. Phase I data reveal bioequivalence [peak concentra-
tion and area under the curve (AUC)] between 200 mg of 
micronized fenofibrate and 135 mg of TriLipix regardless 
of meals. The active drug, fenofibric acid, enters intestinal 
enterocytes in addition attaching to albumin and delivered 
to the liver, adipocytes and the vascular endothelium. The 
half-life of fenofibric acid is 20 hours allowing for once 
daily dosing.
The commonly used fibrates in the US are gemfibrozil 
and fenofibrate. Both gemfibrozil and fenofibrate undergo 
glucuronidation in the liver through different enzymatic 
pathways and are excreted mainly in the urine and to a 
minor degree in feces. Gemfibrozil has a significant com-
petitive effect on statin, TZD and ezitimibe metabolism 
and is associated with a doubling of peak statin serum 
concentration and AUC, increasing exposure and risk of 
muscle toxicity. Fenofibric acid does not compete with 
statin metabolism or increase statin levels and has no 
other known drug–drug interactions except modestly with 
warfarin.62–64 Like fenofibrate, TriLipix does not appear 
to increase risk of muscle, renal or hepatic toxicity. There 
are no differences in pharmacokinetics between males and 
females. Dose adjustment in those with mild to moderate 
renal impairment is recommended (45 mg dose). TriLipix 
has not been studied specifically in the elderly but the 
minimal amount of data available reveals similar pharma-
cokinetics, with slightly decreased Cmax (peak concentra-
tion) and AUC with slightly prolonged half-life compared 
with younger subjects. There are no recommended dosage 
adjustments in the geriatric population; however, since 
renal impairment is more likely in the elderly dose should 
be selected on the basis of renal function and subsequent 
monitoring should be performed. It has not been studied 
in the pediatric population.
TriLipix efficacy and safety when administered with 
statins was evaluated in three 12-week long, multi-center, 
placebo-controlled, double-blind Phase III studies.65–67 One 
52-week, long-term, open-label extension study in 2698 
patients with mixed dyslipidemia68 has also been reported. 
Each study compared the efficacy of (1) 135 mg/dL 
of TriLipix co-administered with either a low or interme-
diate-dose statin versus (2) TriLipix alone or (3) statin Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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monotherapy at the same dose on coronary heart disease 
lipid risk factors. A smaller group of patients received high-
dose statin monotherapy. The statin doses in each study were 
rosuvastatin 10 and 20 mg, simvastatin 20 and 40 mg, and 
atorvastatin 20 and 40 mg. The subjects were enrolled for 22 
weeks which included a 6-week diet run-in/washout period, 
a 12-week treatment period, and a 30-day safety follow-up 
period. Patients who completed the 12-week treatment 
period were eligible to participate in the 52-week long-term 
study. The mean age in all studies was 54.9 years and there 
was an equal distribution of men and women. The primary 
efficacy end-points for the studies were mean percent 
changes from baseline in HDL, TG, and LDL. Statistically 
significant positive differences were observed for all three 
efficacy comparisons at both doses of combination therapy 
in all studies versus either form of monotherapy. There were 
no differences in the safety profiles between the mono- and 
the combination therapies and no evidence of, or signals 
consistent with, hepatic or muscle toxicity were identified. 
Studies already noted using TriLipix in combination with 
statins improved overall atherogenic profiles in subjects 
with mixed or combined dyslipidemia as expected, without 
significantly increased side effect or safety concerns. There 
was no evidence of increased organ toxicity.
Conclusion
We appear to have reached maximum benefit (30% to 35% RRR 
for CV events) from the most aggressive statin monotherapy in 
the secondary risk population. Considering the tens of millions 
of potential patients at risk of CV disease and events, we should 
be curious as to how these results can be improved. There is 
substantial information on risk imparted by non-LDL factors 
including TG and HDL. Non-HDL has now been identified as 
a stronger risk predictor of CV events than LDL, and has an 
NCEP ATP defined goal. These factors can be addressed by a 
variety of pharmacologic approaches including combination 
therapy in addition to therapeutic lifestyle modification. The 
American Diabetes Association and the American College of 
Cardiology now recommend the consideration of combination 
lipid-modifying therapy, especially in those with elevated TG 
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and non-HDL, in patients with CAD.69 TriLipix (fenofibric 
acid) recently received FDA approval for both mono- and 
combination therapy with low and medium dose statins. Trial 
data reveal excellent efficacy on lipid/lipoproteins as well as 
markers of inflammation, alone and in combination. Data do 
not reveal increased risk of muscle, renal or hepatic toxicity. 
This should encourage health care professionals, especially 
those concerned with prior lack of adequate safety data, to 
consider more aggressive lipid-modifying combination treat-
ment with statin and fenofibric acid (TriLipix) in appropriate 
patients to further reduce residual risk for CV events.
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